Translation from the Slovak language

Approved text to the decision on transfer, file No.: 2016/00245-TR

Rectangular stamp with the text:
State Institute for Drug Control
825 08 Bratislava, Kvetná 11
-7/4-
(illegible signature)

**SUMMARY OF CHARACTERISTICS OF THE MEDICINE**

18 April 2016

**1. MEDICINE NAME**

**VACDETA**
40 IU/0.5 ml injection suspension
vaccine against tetanus (adsorbed)

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION OF THE MEDICINE**

One dose (0.5 ml) contains:
tetanus anatoxin..... not less than 40 IU
aluminium hydroxide (adsorbent)..... not more than 0.7 mg $Al^{3+}$

For a full list of adjuvants, see section 6.1.

**3. PHARMACEUTICAL FORM**

Suspension for injection.
The vaccine is a homogeneous cream-coloured suspension.

**4. CLINICAL PARTICULARS**
**4.1 Therapeutic indications**

VACTETA is indicated for active immunization against tetanus (primary vaccination and revaccination) or post-traumatic prophylaxis in children and adults with undetected or non-complete preventive immunization against tetanus.

**4.2 Dosage and method of administration**

Dosage

The same dose (0.5 ml) is given to infants, children, adolescents and adults.

**Primary tetanus vaccination**

(a) is performed in persons who have never been vaccinated against tetanus or have been vaccinated more than 10 years ago;
(b) in children less than one year of age for whom, for medical reasons, vaccination with combination vaccines against diphtheria, tetanus and black cough or diphtheria and tetanus can not be carried out.

A total of 3 doses (0.5 ml) of the vaccine are given:
- 1st dose (from 2 months of age): 0.5 ml,
- 2nd dose after 4 to 6 weeks after the first dose: 0.5 ml
- 3rd dose after 6 to 12 months after the second dose: 0.5 ml.

**Re-vaccination against tetanus**

*Pediatric population*
Re-vaccination is performed by using one dose in the sixth year of the child's age and at the age of thirteen of the child, and thereafter every 10-15 years.

*Adults*
Re-vaccination is carried out every 10-15 years namely one dose (0.5 ml) of the vaccine.

Re-vaccination with combined vaccines is performed with regard to the indications and time intervals applicable to the antigens contained in the combined vaccine.

**Post-exposure tetanus prophylaxis:**

In the case of tetanus immunoprophylaxis in injuries, lesions or non-healing wounds in case of which there is a danger of tetanus disease, and furthermore against some healing performances, in particular rectal and colon surgery (depending on the patient's vaccination status), only tetanus vaccine or tetanus vaccine simultaneously with human anti-tetanus immunoglobulin is administered.

**Post-traumatic prophylaxis of individuals depends on the time of administration of the last dose of tetanus vaccine:**

(a) in case of completed of tetanus immunization:

Last administration within 5 years before injury: no vaccination is required.
Last administration 5 to 10 years before injury: 1 dose (0.5 ml) of the vaccine.
Last administration more than 10 years before injury: 1 dose (0.5ml) of the vaccine simultaneously with 1 dose (250 IU) of human anti-tetanus immunoglobulin. Then the vaccination continues by administration of the second and the third dose at the above-indicated primary vaccination intervals.

In case of a small and clean wound, it is not necessary to administer human immunoglobulin against tetanus.

(b) in case of non-completed preventive immunization against tetanus:

One dose (0.5 ml) of tetanus vaccine is administered to the patients who received 1 dose within 3 to 6 weeks before the injury or 2 doses, within the time period of 3 weeks to 10 months before the injury. In case of incompletely vaccinated patients with other intervals than above, one dose of tetanus vaccine (0.5 ml) and one dose (250 IU) of human anti-tetanus immunoglobulin are administered. Then the vaccination continues by administration of the second and the third dose at the above-indicated primary vaccination intervals.

The physician will decide on possible post-exposure treatment based on the patient's clinical condition and in accordance with national recommendations.

Method of administration

Due to the adsorption nature of the vaccine, intramuscular application is recommended to minimize the local reactions. It can also be applied deeply subcutaneously.

The most suitable place of application is the anterolateral side of the thigh in small children and the deltoid area in older children, adolescents and adults.
It must not be administered intradermally and intravascularly! Make sure the needle does not penetrate into blood vessel!

## 4.3 Contraindications

- Hypersensitivity to the drug or to any of the adjuvants, listed in section 6.1.
- Acute fever illness - mild forms of infection are not contraindications to vaccination.

Rectangular stamp with the text:
State Institute for Drug Control
825 08 Bratislava, Kvetná 11
-7/4-

- In case of ongoing chronic disease, the vaccination must be postponed until symptoms of the disease are corrected
- Suspection of infection (other than tetanus) within the incubation period.
- Thrombocytopenia or neurological disorders after previous vaccination.
- Vaccination against tetanus within the last 5 years.
- In case of injuries there are only a few absolute contraindications when vaccine is administered (there are known severe allergic reactions to any of its components not localized only at the site of application).

Given the high risk of tetanus infection, contraindications should be minimized, especially in the event of injury. If there is any contraindication for VACTETA vaccination, it is necessary to assess the risk associated with vaccination in relation to the risk of infection. In case of injury and determination of the contraindications for VACTETA, human immunoglobulin against tetanus should be administered immediately.

## 4.4 Special warnings and precautions for use

Vaccination should be postponed in case of fever, an acute disease, particularly of infectious origin or chronic disease progression, unless there is a lethal risk associated with tetanus disease.

As in case of other injectable vaccines, medication should be available in case of possible anaphylactic shock after administration of the vaccine.

Immunosuppressive therapy or immunodeficiency may induce a reduction of the immune response to the vaccine administration. Therefore, it is recommended to wait and make vaccination after completing the therapy, respectively, to make sure that the person concerned is adequately protected.

Vaccination of patients with chronic immunosuppression, such as HIV infection, is recommended if the disease allows to get an immune response (although only limited).

To prevent hypersensitivity reactions, the vaccine is not administered to adults who have been vaccinated during the last five years according to the primary vaccination schedule or re-vaccinated.

After administration of the injection, the patient must remain under medical supervision for 30 minutes.

Thiomersal (an organic mercury compound) is used in the manufacture of this medicine and its residues are present in the drug. Therefore, allergic reactions may occur.

## 4.5 Medical and other interactions

No contraindications of administration of VACTETA with other routine vaccines during one vaccination when given at different body sites have been identified.

## 4.6 Fertility, pregnancy and lactation

Pregnancy
During pregnancy, only patients in the indicated cases (in the case of injuries) should be vaccinated against tetanus.
For women who received the first or second dose before their pregnancy was confirmed, the vaccination schedule must be completed during pregnancy. Pregnant women who have been vaccinated more than 10 years ago should be vaccinated in the second trimester of pregnancy.

Breastfeeding
Anti-tetanus antibodies are secreted into breast milk and can be transferred to the newborn.

Rectangular stamp with the text:
State Institute for Drug Control
825 08 Bratislava, Kvetná 11
-7/4-

## 4.7 Effects on ability to drive and use machines

VACTETA has no or has a negligible influence on the ability to drive vehicle and operate machines.

## 4.8 Adverse effects

Very rare side effects (affects less than 1 of 10,000 patients).

Blood and lymphatic system disorders
• Thrombocytopenia

Immune system disorders
• Anaphylactic shock
• Anaphylactic reaction
• Hypersensitivity reaction

Nervous system disorders
• Central and peripheral nervous system disorders such as headache, dizziness, brachial neuritis and Guillain-Barré syndrome

Respiratory, chest and mediastinum disorders
• Apnoea in preterm infants (born before the 28th week of pregnancy)

Gastrointestinal disorders
• Hypersensitivity reactions of the gastrointestinal system

General disorders and reactions at the site of administration
• Systemic reactions: headache, increased body temperature, chills, marked sweating and fatigue. These symptoms are very rare (<1 of 10,000) and usually disappear after 24-48 hours.
• Local reactions: redness, painful swelling, itching at the injection point. Hypersensitivity reaction of lymphatic tissue such as itching may occur. Such reactions are most frequent in repeatedly vaccinated persons. Extremely rarely, a subcutaneous nodule may occur, sometimes producing an aseptic abscess (1: 100,000). The subcutaneous nodule disappears within 6 weeks, may result in hypersensitivity to aluminium.

Reporting of suspicion of undesirable reactions
Reporting of suspicion of undesirable reactions after medicine registration is important. It allows continuous monitoring of the benefit/risk ratio of the medicine. Healthcare professionals are required to report any suspicion of undesirable reactions through the national reporting system listed in Annex V.

### 4.9 Overdosage

No case of overdose has been reported. Overdose is unlikely. The vaccine is supplied in ampoules containing 1 dose (0.5 ml).

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties
**Pharmacotherapeutic group:** Vaccines against tetanus, ATC code: J07AM01

Rectangular stamp with the text:
State Institute for Drug Control
825 08 Bratislava, Kvetná 11
-7/4-

Mechanism of action

The drug in VACTETA is a tetanus toxoid (T) adsorbed on aluminum hydroxide. The toxoid is obtained by inactivating bacterial toxins originating from the culture of bacteria *Clostridium tetani* by formaldehyde. Toxoid retains the antigenic properties of the natural toxin but lacks pathogenicity. Thus, tetanus toxoid induces an immune response, consisting in antibody production (seroconversion), and triggers the mechanism of immune memory. Immunizing properties of the vaccine are supported by aluminum hydroxide (adsorbent).

One dose of VACTETA does not protect against tetanus. If after two to four weeks a second dose of this vaccine or combination vaccine against diphtheria and tetanus follows and then the third dose, 90% of the patients will develop immunity. However, it takes only a short time. The additional dose provides immunity for up to 10 years.
Booster doses (re-vaccinations) provide long-term protection against the disease.

The vaccine complies with the WHO requirements for the tetanus vaccine.

### 5.2 Pharmacokinetic properties
Not applicable.

### 5.3 Preclinical safety data

Data from available published animal studies obtained when using the combined vaccines with the same antigen, including single and repeated applications and local tolerance studies, did not reveal any special hazard or organ toxicity.

## 6. PHARMACEUTICAL INFORMATION

### 6.1 List of adjuvants

Sodium chloride
Water for injections

Adsorbent: see section 2.

**6.2 Incompatibility**
No compatibility studies have been performed, so this medicine should not be mixed with other medicines, vaccines or immunoglobins.

**6.3 Shelf life**
3 years

**6.4 Special precautions for storage**
Store in a refrigerator (2° C - 8° C).
Do not store in the freezer.

**6.5 Type of package and contents of packing**

Ampoules made of type 1 glass.
Package size:

Rectangular stamp with the text:
State Institute for Drug Control
825 08 Bratislava, Kvetná 11
-7/4-

1 x 0.5 ml ampoule
5 x 0.5 ml ampoule

Not all packing sizes are necessarily marketed.

**6.6 Special precautions for disposal and other handling the medicine**

After shaking, the vaccine is a milky, homogeneous suspension, creamy shade.
During storage, white sediment with clear liquid on the surface can be observed.

Before application shake the ampoule properly until a homogeneous suspension is obtained.

The vaccine should be visually inspected for the presence of foreign particles and/or a change in physical appearance of the vaccine. The vaccine must not be used in case of any change of its appearance.

Any unused medicine or waste material from the medicine should be disposed in accordance with the national requirements.

**7. MARKETING AUTHORIZATION HOLDER**

BIODRUG s.r.o.
Boženy Nemcovej 8
811 04 Bratislava, Slovak Republic

**8. MARKETING AUTHORIZATION NUMBER**

59/0170/15-S

**9. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION**

Date of the first registration: 7 July 2015
Date of the last registration prolongation:

**10. DATE OF TEXT REVISION**

April 2016

Block stamp:
I certify that this document literary corresponds to the presented original ~~(certified copy)~~ consisting of 6 pages. It is the complete (~~partial)~~ copy. No (T~~he following)~~ modifications, supplements were made in the document.
In Bratislava, on 9 October 2018

Round seal with the text: JUDr. Lýdia Kliská Uhrinová - Notary – Bratislava III -2-

*/illegible signature/*
Rectangular stamp with the text:
JUDr. Magdaléna Kršková
notarial trainee
entrusted by the notary
JUDr. Lýdia Kliská Uhrinová

Round seal with the text: JUDr. Lýdia Kliská Uhrinová - Notary – Bratislava III -2-

Round seal with the text: JUDr. Lýdia Kliská Uhrinová - Notary – Bratislava III -2-

Round seal with the text: JUDr. Lýdia Kliská Uhrinová - Notary – Bratislava III -2-